Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation, and chemotherapy.

The CML pipeline drugs market research report provides comprehensive information on the therapeutics under development for CML, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for CML and features dormant and discontinued projects.

CML Pipeline Drugs Market Segmentation by Targets

Some of the targets of the CML pipeline drugs market are Bcr-Abl Tyrosine Kinase, Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing Interleukin 3 Receptor Subunit Alpha, CD3, Cells Expressing Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing Wilms Tumor Protein, and others.

CML Pipeline Drugs Market Analysis, by Targets

For more CML pipeline drugs market target insights, download a free report sample

CML Pipeline Drugs Market Segmentation by Mechanisms of Actions

Some of the key mechanisms of action of the CML pipeline drugs market are Bcr-Abl Tyrosine Kinase Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, CD3 Agonist, Cytotoxic To Cells Expressing Mast/Stem Cell Growth Factor Receptor Kit, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Wilms Tumor Protein, and others.

CML Pipeline Drugs Market Analysis, by Mechanism of Action

For more mechanisms of action insights into the CML pipeline drugs market, download a free report sample

CML Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the CML pipeline drugs market are oral, intravenous, parenteral, subcutaneous, intraperitoneal, intradermal, intralesional, intramuscular, and others.

CML Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the CML pipeline drugs market, download a free report sample

CML Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the CML pipeline drugs market are Small Molecule, Cell Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Monoclonal Antibody, Fusion Protein, and others.

CML Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the CML pipeline drugs market, download a free report sample

CML Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the CML pipeline drugs market are Ascentage Pharma Group International, Bristol-Myers Squibb Co, Millennium Pharmaceuticals Inc, Pfizer Inc, AbbVie Inc, Handa Pharmaceuticals LLC, Ilyang Pharmaceutical Co Ltd, Nanocopoeia LLC, and others.

CML Pipeline Drugs Market Analysis, by Companies

To know more about the CML pipeline drugs market companies, download a free report sample

CML Pipeline Drugs Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of CML.
• The pipeline guide reviews pipeline therapeutics for CML by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in CML therapeutics and enlists CML in their major and minor projects.
• The pipeline guide evaluates CML therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates CML in the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for CML

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for CML.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the CML pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.